KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Profit After Tax (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Profit After Tax data on record, last reported at $1.2 billion in Q4 2025.

  • For Q4 2025, Profit After Tax rose 30.46% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $4.0 billion, up 838.09%, while the annual FY2025 figure was $4.0 billion, 838.09% up from the prior year.
  • Profit After Tax reached $1.2 billion in Q4 2025 per VRTX's latest filing, up from $1.1 billion in the prior quarter.
  • Across five years, Profit After Tax topped out at $1.2 billion in Q4 2025 and bottomed at -$3.6 billion in Q2 2024.
  • Average Profit After Tax over 5 years is $635.1 million, with a median of $882.4 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: surged 1111.08% in 2022, then tumbled 492.44% in 2024.
  • A 5-year view of Profit After Tax shows it stood at $770.1 million in 2021, then increased by 6.34% to $818.9 million in 2022, then increased by 18.31% to $968.8 million in 2023, then decreased by 5.76% to $913.0 million in 2024, then skyrocketed by 30.46% to $1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.0 billion in Q2 2025.